0.01% 0.000100

X 4 Pharmaceuticals Inc (XFOR)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

X 4 Pharmaceuticals Inc

857-529-8300

61 NORTH BEACON STREET, BOSTON, MA

Prossima data di guadagno

Ultimi documenti SEC

XFOR's Discussions on Twitter

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-30	Ripresa	B. Riley Securities	Buy
2022-12-22	Iniziato	Cantor Fitzgerald	Overweight
2022-12-12	Iniziato	Piper Sandler	Overweight
2019-12-23	Iniziato	Oppenheimer	Outperform
2019-12-18	Iniziato	ROTH Capital	Buy
2019-12-09	Aggiornamento	Citigroup	Neutral → Buy
2019-12-05	Iniziato	B. Riley FBR	Buy
2019-06-07	Iniziato	Stifel	Buy
2019-06-05	Iniziato	Cowen	Outperform

Mostra tutto

X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie

X 4 Pharmaceuticals Inc Azioni (XFOR) Dati Finanziari

X 4 Pharmaceuticals Inc (XFOR)

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie

Market Watch: X4 Pharmaceuticals Inc (XFOR)’s Noteworthy Gain, Closing at 0.71 - The Dwinnex

United States Intravenous Iron Drug Market By Application - Third Eye News

North America Medulloblastoma Drug Market By Application – news - Vaccine Storage & Packaging ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by TD Asset Management Inc - Defense World

North America Drug Discovery Outsourcing Market Size USD 3.4 Bn in 2023| CAGR of 7.2%| USD 5.93 Bn by 2032 - Third Eye News

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with - The Bakersfield Californian

Alkem joins $3 bn race for JB Chem as Torrent pauses talks - The Economic Times

North America Addictions Therapeutics Market By Application - Third Eye News

United States 1,3-Dioxane-4-Aceticacid, 6-(Cyanomethyl)-2,2-Dimethyl-, 1,1-Dimethylethyl Ester, (4R,6R) Market Size, Share, Growth & Forecast – Third Eye News - Third Eye News

You might want to take a look at X4 Pharmaceuticals Inc (XFOR) now - SETE News

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - Chronicle-Tribune

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

X4 Pharmaceuticals Inc (XFOR) stock on the rise: An overview - US Post News

BMRN: Undervalued Biotech Stocks Ready for a Breakout - StockNews.com

Pharmaceutical Intermediates Market Size To Reach USD 14.0 - GlobeNewswire

Ratios Revealed: Decoding X4 Pharmaceuticals Inc (XFOR)’s Financial Health - The Dwinnex

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO - StockTitan

Anosmia Market Innovations Investigated by Size, Share, Industry Analysis, Segments And Forecast To 2033 - WhaTech

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules - StockTitan

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market 2024 - openPR

X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 1.3% - MarketBeat

The time has not yet come to remove your chips from the table: X4 Pharmaceuticals Inc (XFOR) - SETE News

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - Quantisnow

EVP Research Swayze Eric acquired $425 worth of shares (11 units at $38.64), increasing direct ownership by 0.03% to 34,907 units (SEC Form 4) - Quantisnow

Amendment: EVP, Finance & CFO Hougen Elizabeth L sold $107,105 worth of shares (2,162 units at $49.54), decreasing direct ownership by 2% to 92,868 units (SEC Form 4) - Quantisnow

Potential Price Increase for Opendoor Technologies Inc (OPEN) After Recent Insider Activity - Knox Daily

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - StockTitan

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

EVP, Chief Development Officer Geary Richard S sold $32,159 worth of shares (651 units at $49.40), decreasing direct ownership by 0.76% to 84,823 units (SEC Form 4) - Quantisnow

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Trading Day Review: X4 Pharmaceuticals Inc (XFOR) Gains Momentum, Closing at 0.70 - The Dwinnex

X4 Pharmaceuticals Inc (XFOR)’s stock rises to 0.70 per share - US Post News

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech

Alpha Methyldopa Market Advancements Highlighted by Size, Share, Growth, Trends and Industry Forecast (2024... - WhaTech

mRNA Cancer Vaccines And Therapeutics Global Market In The New Analysis By Leading Research Firm - WhaTech

Top 10 pharma companies in India by market cap - Forbes India

North America Drug for Organ Rejection Prophylaxis Market By Application : A Global Perspective on Regional Markets - அக்னி செய்திகள்

Coccidioidomycosis Drug Market Size, Market Resilience in Times of Disruption (2024-2034) - Cineglit

Coccidioidomycosis Drug Market Size, Market Resilience in Times of Disruption (2024-2034) - அக்னி செய்திகள்

North America Pharmaceutical Grade Apixaban Market By Application : Industry Analysis and Forecast 2031 - அக்னி செய்திகள்

Recursion Pharmaceuticals To Acquire Exscientia In $688 Million Deal - Finimize

North America Pharmaceutical Grade Dapagliflozin Market By Application : Size, Trends, Share and Forecast 2031 - அக்னி செய்திகள்

Gen X Is So Unprepared For Retirement They're Being Called 'Silver Squatters' Because 1 in 5 Are Counting On Help From Their Kids - Yahoo Finance

Global Ketolides Market 2024 Report Explores By Size, Drivers, Trends, Competitors - WhaTech

Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference - Quantisnow

X 4 Pharmaceuticals Inc Azioni (XFOR) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a XFOR